Literature DB >> 26875112

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.

Liza C Villaruz1, Mark A Socinski2.   

Abstract

Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. This approval was based on the results of a phase III clinical trial showing superior response rates compared with solvent-based paclitaxel in combination with carboplatin. This review will focus on the early development and clinical data to date supporting the use of nab-paclitaxel in advanced NSCLC. The clinical question central to this review is whether nab-paclitaxel has a place in the current therapeutic landscape of advanced NSCLC.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carboplatin; Elderly; Nab-paclitaxel; Neuropathy; Non-small cell lung cancer (NSCLC); Squamous cell histology

Mesh：

Substances：

Year:  2016        PMID： 26875112      PMCID： PMC4844000          DOI： 10.1016/j.ejca.2015.12.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  72 in total

1.  Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway.

Authors:  C Tiruppathi; W Song; M Bergenfeldt; P Sass; A B Malik
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

2.  Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo.

Authors:  W Schubert; P G Frank; B Razani; D S Park; C W Chow; M P Lisanti
Journal:  J Biol Chem       Date:  2001-10-31       Impact factor: 5.157

3.  Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.

Authors:  Denis Moro-Sibilot; Egbert Smit; Javier de Castro Carpeño; Krzysztof Lesniewski-Kmak; Joachim Aerts; Rosa Villatoro; Kees Kraaij; Karim Nacerddine; Yulia Dyachkova; Karen T Smith; Kaisa Taipale; Allicia C Girvan; Carla Visseren-Grul; Philipp A Schnabel
Journal:  Lung Cancer       Date:  2015-02-21       Impact factor: 5.705

4.  Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Authors:  Nuhad K Ibrahim; Neil Desai; Sewa Legha; Patrick Soon-Shiong; Richard L Theriault; Edgardo Rivera; Bita Esmaeli; Sigrid E Ring; Agop Bedikian; Gabriel N Hortobagyi; Julie A Ellerhorst
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

5.  Suspected anaphylactic reaction to Cremophor EL.

Authors:  D Dye; J Watkins
Journal:  Br Med J       Date:  1980-06-07

6.  Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

Authors:  David R Gandara; Tomoya Kawaguchi; John Crowley; James Moon; Kiyoyuki Furuse; Masaaki Kawahara; Satoshi Teramukai; Yuichiro Ohe; Kaoru Kubota; Stephen K Williamson; Oliver Gautschi; Heinz Josef Lenz; Howard L McLeod; Primo N Lara; Charles Arthur Coltman; Masahiro Fukuoka; Nagahiro Saijo; Masanori Fukushima; Philip C Mack
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

7.  Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study.

Authors:  A Carrato; A Vergnenègre; M Thomas; K McBride; J Medina; G Cruciani
Journal:  Curr Med Res Opin       Date:  2013-11-18       Impact factor: 2.580

8.  Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States.

Authors:  Kathleen Lang; Martin D Marciniak; Doug Faries; Michael Stokes; Don Buesching; Craig Earle; Joseph Treat; Nathalie Morissette; David Thompson
Journal:  Lung Cancer       Date:  2008-07-22       Impact factor: 5.705

Review 9.  Taxol: a novel investigational antimicrotubule agent.

Authors:  E K Rowinsky; L A Cazenave; R C Donehower
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

10.  Hypersensitivity reactions from taxol.

Authors:  R B Weiss; R C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; J R Baker; D A Van Echo; D D Von Hoff; B Leyland-Jones
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544
View more
  7 in total

1.  First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis.

Authors:  Lisa M Hess; Amy M DeLozier; Fanni Natanegara; Xiaofei Wang; Victoria Soldatenkova; Alan Brnabic; Stephen L Able; Jacqueline Brown
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

2.  Long non-coding RNA PRNCR1 modulates non-small cell lung cancer cell proliferation, apoptosis, migration, invasion, and EMT through PRNCR1/miR-126-5p/MTDH axis.

Authors:  Ran Guo; Tongchen Hu; Yanheng Liu; Yinzai He; Yanling Cao
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

3.  Tubeimoside-1 inhibits the proliferation and metastasis by promoting miR-126-5p expression in non-small cell lung cancer cells.

Authors:  Hanbing Shi; Hongxia Bi; Xingyuan Sun; Haiying Dong; Yunfei Jiang; Haijun Mu; Wei Li; Guohua Liu; Ruizhi Gao; Jiang Su
Journal:  Oncol Lett       Date:  2018-06-29       Impact factor: 2.967

4.  Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study.

Authors:  Shanshan Qin; Hui Yu; Xianghua Wu; Zhiguo Luo; Huijie Wang; Si Sun; Mingzhu Huang; Jia Jin; Zhonghua Tao; Jie Qiao; Yu Feng; Jialei Wang; Jianhua Chang
Journal:  Chin J Cancer Res       Date:  2019-04       Impact factor: 5.087

5.  Multiline treatment of advanced squamous cell carcinoma of the lung: A case report and review of the literature.

Authors:  Xin Yang; Ping Peng; Li Zhang
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

6.  ENKUR expression induced by chemically synthesized cinobufotalin suppresses malignant activities of hepatocellular carcinoma by modulating β-catenin/c-Jun/MYH9/USP7/c-Myc axis.

Authors:  Rentao Hou; Yonghao Li; Xiaojun Luo; Wan Zhang; Huiling Yang; Yewei Zhang; Jiahao Liu; Shaohua Liu; Siyuan Han; Chen Liu; Yun Huang; Zhen Liu; Aimin Li; Weiyi Fang
Journal:  Int J Biol Sci       Date:  2022-03-21       Impact factor: 6.580

7.  The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.

Authors:  Puyuan Xing; Yixiang Zhu; Ling Shan; Sipeng Chen; Xuezhi Hao; Junling Li
Journal:  Oncotarget       Date:  2017-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.